Literature DB >> 3052565

Diphencyprone in the treatment of long-standing alopecia areata.

S M Hull1, J F Norris.   

Abstract

Thirty-six patients with alopecia areata of 1-54 years duration entered a study of treatment with the contact allergen diphencyprone for 8 months. Following sensitization the diphencyprone was applied to one half of the scalp at weekly intervals, the other half acting as a control. Once hair growth was established on one side, the other side was treated. Seven patients did not continue treatment and one patient showed spontaneous regrowth. Of the remaining 28 patients who persisted with treatments, fourteen (50%) regrew hair on the treated side; eight (29%) had a cosmetically acceptable result with the regrowth of terminal hair over the whole scalp. No statistically significant differences were found in age or duration of alopecia between those who regrew and those who did not. We have found diphencyprone to be an effective stimulator of hair growth in patients with severe and long-standing alopecia areata.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052565     DOI: 10.1111/j.1365-2133.1988.tb03230.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

1.  Topical immunotherapy with contact allergens in alopecia areata: evidence for non-specific systemic suppression of cellular immune reactions.

Authors:  E B Bröcker; S M John; D Steinhausen; H Hamm
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

Review 2.  Alopecia Areata: a Comprehensive Review of Pathogenesis and Management.

Authors:  Ralph M Trüeb; Maria Fernanda Reis Gavazzoni Dias
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  Application of Topical Immunotherapy in the Treatment of Alopecia Areata: A Review and Update.

Authors:  Thipprapai Mahasaksiri; Chaninan Kositkuljorn; Tanaporn Anuntrangsee; Poonkiat Suchonwanit
Journal:  Drug Des Devel Ther       Date:  2021-03-23       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.